Autobahn Acquires Global Rights to Astellas’ ASP3652 to Bolster its Brain Targeting Chemistry Platform

 Autobahn Acquires Global Rights to Astellas’ ASP3652 to Bolster its Brain Targeting Chemistry Platform

Shots:

  • Autobahn acquires global IP, development, and regulatory rights to ASP3652 to strengthen its brain-targeting chemistry platform. The addition of ASP3652 will accelerate the delivery of next-generation brain-targeting prodrugs for CNS disorders, particularly MS
  • ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated prodrug conversion to enable the delivery of small molecules across the BBB. The company may develop ASP3652 in combination with multiple pipeline programs, including Autobahn’s TRβ agonists for MS
  • ASP3652 is a FAAH inhibitor, previously been evaluated across 10 clinical studies in ~200 patients

Click here to­ read full press release/ article | Ref: BUSINESS WIRE | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post